Recalls & Warnings
ConsumerLab.com is keeping you informed with current product recalls and warnings.
Latest Posted May 30, 2024
Young Living Essential Oils Agrees to Pay $5 Million to Settle Lawsuit
Young Living Essential Oils has agreed to pay up to $5 million to settle a class action lawsuit that charged the company with promoting its essential oils to reduce stress and anxiety, improve sleep, and other health-related claims without reliable scientific evidence.
The lawsuit also alleged that Young Living marketed its lavender, peppermint, and other essential oils as “therapeutic grade,” without providing evidence to support this claim, citing a ruling by the National Advertising Review Board in November 2020 that Young Living should discontinue use of this term because it was “unsupported.” At that time, Young Living agreed to comply and permanently discontinue the claim that its products are therapeutic. The company was warned by the FDA in 2022 for making claims its products could treat seasonal allergies, kidney stones, and other health conditions.
[See ConsumerLab’s Lavender and Tea Tree Essential Oils Review for tests of products and our Top Picks among essential oils. The Review also discusses the clinical evidence for essential oils for anxiety, sleep, pain, and other conditions.]
As part of the settlement agreement, consumers who purchased Young Living essential oils for personal use between January 1, 2017, through April 25, 2024 are eligible to receive a refund of up to $2 per product up to a maximum of $20. Consumers who wish to submit a claim must do so by June 24, 2024.
For more information, use the link below.
Class Action Settlement: MacNaughton, et al. v. Young Living Essential Oils, LC
See related recalls and warnings:
Young Living Warned for Promoting Essential Oils to Treat Seasonal Allergies, Kidney Stones & More
Sellers of Essential Oils Warned for Claiming to Treat Ebola, Other Diseases
Complaint Submitted to FTC for doTerra Essential Oil COVID Claims
The lawsuit also alleged that Young Living marketed its lavender, peppermint, and other essential oils as “therapeutic grade,” without providing evidence to support this claim, citing a ruling by the National Advertising Review Board in November 2020 that Young Living should discontinue use of this term because it was “unsupported.” At that time, Young Living agreed to comply and permanently discontinue the claim that its products are therapeutic. The company was warned by the FDA in 2022 for making claims its products could treat seasonal allergies, kidney stones, and other health conditions.
[See ConsumerLab’s Lavender and Tea Tree Essential Oils Review for tests of products and our Top Picks among essential oils. The Review also discusses the clinical evidence for essential oils for anxiety, sleep, pain, and other conditions.]
As part of the settlement agreement, consumers who purchased Young Living essential oils for personal use between January 1, 2017, through April 25, 2024 are eligible to receive a refund of up to $2 per product up to a maximum of $20. Consumers who wish to submit a claim must do so by June 24, 2024.
For more information, use the link below.
Class Action Settlement: MacNaughton, et al. v. Young Living Essential Oils, LC
See related recalls and warnings:
Young Living Warned for Promoting Essential Oils to Treat Seasonal Allergies, Kidney Stones & More
Sellers of Essential Oils Warned for Claiming to Treat Ebola, Other Diseases
Complaint Submitted to FTC for doTerra Essential Oil COVID Claims
Other Recent Recalls & Warnings
FTC Challenges Weight-loss Claims for Slim Down Solution
January 24, 2003
Non-Prescription Anti-Hypertension Pills Recalled
January 18, 2003
U.S. Seizes Supplement Illegally Marketed for Virus and Cold Use; FDA Steps Up Activity Against Supplements with False Claims
December 20, 2002
Recall of Calcium Supplement Possibly Contaminated with Antibiotic
December 11, 2002
Company Ordered to Cease Deceptive Marketing of Weight Loss Product
December 10, 2002
Recall Of Selected Store Brand Infant Formula in U.S.
November 04, 2002
FDA Seizes Supplements Claiming to Treat Autism
October 22, 2002
FDA Sends Warning Letters to Seven Online Supplement Sellers For Therapeutic Claims
September 07, 2002
Canadian Recall and Stop-Sale Order on All Kava Products
August 25, 2002
FDA Warns Public About Chinese Diet Pills Containing Fenfluramine
August 15, 2002
For information about reporting serious reactions and problems with medical products to the U.S. Food and Drug Administration through its MedWatch reporting program, please visit the FDA MedWatch website.